Medi-Tate

Olympus Corporation finalized the acquisition of Medi-Tate Ltd., an Israeli medical device company specializing in minimally invasive treatment for benign prostatic hyperplasia (BPH). The acquisition expands Olympus's urology portfolio with the iTind device.

Olympus Corporation announced it has exercised its call option to acquire the remainder of shares in Medi-Tate Ltd., an Israeli medical device company specializing in minimally invasive treatment for benign prostatic hyperplasia. The acquisition aims to expand Olympus' urology business.

Olympus entered into a final agreement with Medi-Tate Ltd., an Israeli medical device manufacturer, including distribution rights and an option to acquire 100% of the company. The investment strengthens Olympus's urology business.

Olympus Corporation has entered into a final agreement to invest in Israeli company Medi-Tate, including distribution rights and a call option to acquire 100% of the company.